On March 4th, 2016, Springer’s Cancer Nanotechnology office promoted the launch of the Nanotechnology Startup Challenge in Cancer (NSC 2 ). This innovation-development model is a partnership among our company, the Center for Advancing Innovation (CAI), MedImmune, the global biologics arm of AstraZeneca, and multiple institutes at the National Institutes of Health (NIH). NSC 2 “crowdsources” talent from around the world to launch startups with near-term, commercially viable cancer nanotechnology inventions, which were developed by the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Biomedical Imaging and Bioengineering (NIBIB). Crowdsourcing is a process in which one uses the internet to engage a large group of people in an activity, such as NSC 2 . For this initiative, CAI engaged universities, industry professionals, foundations, investors, relevant media outlets, seasoned entrepreneurs, and life sciences membership organizations to request that they participate in the challenge. From this outreach, fifty-six key thought leaders have enrolled in NSC 2 as judges, mentors, and/or advisors to challenge teams ( http://www.nscsquared.org/judges.html ). Along with crowdsourcing talent to bolt startups around NIH inventions, NSC 2 will also catalyze the launch of companies around “third-party” cancer nanotechnology inventions, which were conceived and developed outside of the NIH. Twenty-eight robust teams were accepted to the challenge on March 14th, 2016.

中文翻译：

---

瞪羚，独角兽和龙通过纳米技术创业挑战赛与癌症作斗争。

2016年3月4日，施普林格癌症纳米技术办公室推动了癌症纳米技术创业挑战赛（NSC 2）的启动。这种创新发展模式是我们公司，先进创新中心（CAI），MedImmune，阿斯利康的全球生物制剂部门以及国立卫生研究院（NIH）的多个机构之间的合作伙伴关系。NSC 2“聚集”来自世界各地的人才，以启动具有近期商业上可行的癌症纳米技术发明的初创公司，这些发明是由美国国家癌症研究所（NCI），美国国家心肺血液研究所（NHLBI）和美国国家癌症研究所共同开发的。美国国家生物医学成像与生物工程研究所（NIBIB）。众包是一个过程，在该过程中，人们使用Internet来使一大群人参与诸如NSC 2之类的活动。为此，CAI吸引了大学，行业专业人士，基金会，投资者，相关媒体，经验丰富的企业家和生命科学会员组织，要求他们参与挑战。通过这次推广，共有56名主要思想领袖以法官，导师和/或顾问的身份加入了NSC 2，以挑战团队（http://www.nscsquared.org/judges.html）。与众包人才一起围绕NIH发明锁定初创企业，NSC 2还将促进围绕“第三方”癌症纳米技术发明的公司的成立，这些发明是在NIH之外构思和开发的。2016年3月14日，有28个强大的团队接受了挑战。